Dr. Paul Limburg, CMO at Exact Sciences and emeritus professor at Mayo Clinic, discusses advances in colorectal cancer (CRC) screening, including mailed FIT programs to boost screening in rural and underserved populations. He covers developments in multi-target stool testing, addressing gastroenterologists’ skepticism, ensuring follow-up colonoscopies for positive tests, AI integration, microbiome research, and potential direct-to-consumer testing. He also shares insights on transitioning from academic to industry roles and the future of stool-based testing alongside colonoscopy.
Previous ArticleNew AGA guideline streamlines Crohn’s disease treatment (AGA)
Keep Reading
Add A Comment
